CAMP CONTINUATION STUDY/PHASE 2 (CAMPCS/2) PROTOCOL

训练营继续研究/第 2 阶段 (CAMPCS/2) 方案

• 批准号: 7719390
• 负责人: Stanley J Szefler
• 金额: $ 0.42万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719390
• 关键词: Adrenal Cortex Hormones; Age; Breathing; Bronchodilator Agents; Budesonide; Child; Childhood Asthma; Computer Retrieval of Information on Scientific Projects Database; Development; Funding; Grant; Growth; Institution; Intervention Studies; Lung; Nedocromil; Phase; Phase II Clinical Trials; Population Study; Protocols documentation; Randomized; Research; Research Personnel; Resources; Source; Steroids; Time; United States National Institutes of Health; design; programs; treatment duration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Childhood Asthma Management Program (CAMP) Continuation Study 2 (CAMPCS/2) is a four year extension of an ongoing 10 year study of childhood asthma. The original CAMP study was a 4-6 year study of intervention with either budesonide (an inhaled corticosteroid), nedocromil (a non-steroid), or as need bronchodilator therapy alone in the study population of over 1,000 children ages 5-13 years at the time of randomization. The CAMPCS and CAMPCS/2 study is designed to evaluate the effect of this intense treatment period on maximal lung growth and body development.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 儿童哮喘管理项目（CAMP）延续研究2（CAMPCS/2）是一项正在进行的10年儿童哮喘研究的4年扩展。 最初的CAMP研究是一项为期4-6年的研究，在随机化时超过1,000名5-13岁儿童的研究人群中进行布地奈德（一种吸入性皮质类固醇）、奈多罗米（一种非类固醇）或按需单独支气管扩张剂治疗的干预。 CAMPCS和CAMPCS/2研究旨在评价该强化治疗期对最大肺生长和身体发育的影响。